Brief: Achilles Therapeutics Reports Q1 2023 Financial Results And Recent Business Highlights
10/05/2023 12:17
May 10 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND RECENT BUSINESS HIGHLIGHTS
* ACHILLES THERAPEUTICS PLC: CASH POSITION OF $158.5 MILLION
SUPPORTS OPERATIONS INTO MID-2025
* ACHILLES THERAPEUTICS: PHASE I/IIA CLINICAL TRIALS IN
NSCLC,
MELANOMA PROGRESSING WITH ADDITIONAL CLINICAL & TRANSLATIONAL
SCIENCE DATA EXPECTED IN Q4
* ACHILLES THERAPEUTICS PLC: QTRLY LOSS PER SHARE $0.44
Source text for Eikon: ID:nGNX8b6K4B
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement